ACTRN12607000418471
Completed
Phase 2
In patients with chronic hepatitis C, does treatment with oglufanide disodium reduce viral load from baseline value?
Implicit Bioscience Pty Ltd0 sites17 target enrollmentAugust 17, 2007
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Chronic hepatitis C
- Sponsor
- Implicit Bioscience Pty Ltd
- Enrollment
- 17
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Serological evidence of infection with hepatitis C virus (HCV), including anti\-HCV antibodies and viral load at least 100 time sgreate tha the lower limit of detection.
Exclusion Criteria
- •1\. Co\-infection with hepatitis B or human immunodeficiency virus (HIV)
- •2\. Severe liver disease, or liver disease due to other disorders
- •3\. Renal, hepatic or bone marrow dysfunction
- •4\. Active or suspected cancer or histor of malignancy with high risk of recurrence
- •5\. Organ transplant
- •6\. Substance abuse
- •7\. Women of childbearing potential
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Spirulina Platensis in the Treatment of Chronic Hepatitis C Virus (HCV) InfectioACTRN12610000958088Abbass Helmy Charity60
Completed
Phase 2
THE HEP573 STUDY: A randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis CChronic Hepatitis CAlternative and Complementary Medicine - Herbal remediesAlternative and Complementary Medicine - Other alternative and complementary medicineOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12614000966695John Hunter Hospital216
Completed
Phase 4
CHESS - Curing Hepatitis C: Effect on the Endothelium and cardiovaScular riSk - a pilot single arm trial, assessing the effect of hepatitis C virus (HCV) treatment with 12 weeks of paritaprevir/ritonavir/ombitasvir, dasabuvir +/- ribavirin on endothelial function.Hepatitis C virus infectionEndothelial functionInfection - Other infectious diseasesCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12615001167550John Hunter Hospital16
Not yet recruiting
Not Applicable
Efficacy of antiviral therapy in hepatitis C patients aged 70 years or older: multicenter prospective observational studyChronic hepatitis CJPRN-UMIN000017329R24 Liver Conference516
Completed
Not Applicable
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (HCC) USING PEG-INTERFERON ALPHA 2B AND RIBAVIRINEPER-039-01SCHERING PLOUGH RESEARCH INSTITUTE,